Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 232 institutions reported holding it in 13F filings for Q3 2026, worth $2.83B in total; ARK Invest is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 14, 2026, 1:14 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $264.5M (314.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Nov 30, 2025 | Nov 30, 2024 | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 28, 2026 | Jan 13, 2025 | Feb 15, 2024 | Feb 9, 2023 | Jan 27, 2022 |
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M |
| Operating expenses | $369.6M | $267.6M | $232.1M | $222.5M | $147.6M |
| Research and development | $316.9M | $221.6M | $189.1M | $184.5M | $116.4M |
| Selling, general and administrative | $52.7M | $45.9M | $42.9M | $38.0M | $31.2M |
| Operating income | -$285.7M | -$213.0M | -$155.1M | -$183.9M | -$117.9M |
| Income tax | $760.0K | $270.0K | – | $0 | $131.0K |
| Net income | -$264.5M | -$193.6M | -$143.9M | -$180.4M | -$117.2M |
| EPS, basic | $-3.05 | $-2.88 | $-2.65 | $-3.71 | – |
| EPS, diluted | $-3.05 | $-2.88 | $-2.65 | $-3.71 | – |
| Weighted shares, basic | 86.7M | 67.1M | 54.3M | 48.6M | – |
| Weighted shares, diluted | 86.7M | 67.1M | 54.3M | 48.6M | – |
| Margins and growth | |||||
| Operating margin | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% |
| Net margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% |
| Revenue growth, year over year | +54.0% | −29.1% | +99.3% | +29.8% | +66.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Nov 30, 2025 | Nov 30, 2024 | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 28, 2026 | Jan 13, 2025 | Feb 15, 2024 | Feb 9, 2023 | Jan 27, 2022 |
| Cash and equivalents | $247.0M | $110.0M | $54.6M | $64.5M | $80.5M |
| Short-term investments | – | – | – | $244.7M | $215.2M |
| Accounts receivable | – | – | – | $0 | $6.00M |
| Total current assets | $606.8M | $619.4M | $295.5M | $318.4M | $311.1M |
| Property, plant and equipment | $22.5M | $17.8M | $16.8M | $17.2M | $11.3M |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M |
| Accounts payable | $11.2M | $11.5M | $6.40M | $5.06M | $6.65M |
| Total current liabilities | $86.5M | $95.9M | $87.0M | $70.7M | $66.3M |
| Total liabilities | $149.4M | $142.3M | $155.1M | $113.1M | $134.5M |
| Shareholders' equity | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Nov 30, 2025 | Nov 30, 2024 | Nov 30, 2023 | Nov 30, 2022 | Nov 30, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 28, 2026 | Jan 13, 2025 | Feb 15, 2024 | Feb 9, 2023 | Jan 27, 2022 |
| Operating cash flow | -$249.5M | -$172.6M | -$81.4M | -$159.8M | -$84.4M |
| Capital expenditures | $14.0M | $9.27M | $8.40M | $12.2M | $5.66M |
| Free cash flow | -$263.5M | -$181.9M | -$89.8M | -$172.1M | -$90.0M |
| Depreciation and amortization | $8.74M | $9.32M | $7.53M | $5.35M | $2.79M |
| Stock-based compensation | $38.0M | $33.9M | $33.7M | $28.1M | $15.8M |
| Investing cash flow | $147.9M | -$257.7M | $68.3M | $27.2M | -$108.3M |
| Financing cash flow | $238.6M | $485.7M | $3.22M | $117.2M | $153.9M |
| Net change in cash | $137.0M | $55.4M | -$9.85M | -$15.4M | -$38.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 45.2% | 62.2% | 43.7% | 72.8% | 53.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Sep 30, 2026 | 109.2M | +42.1% | SEC |
| Jun 30, 2026 | 103.8M | +35.8% | SEC |
| Apr 1, 2026 | 103.4M | +35.6% | SEC |
| Jan 23, 2026 | 102.8M | +35.5% | SEC |
| Sep 30, 2025 | 76.9M | +8.5% | SEC |
| Jun 30, 2025 | 76.4M | +18.7% | SEC |
| Apr 1, 2025 | 76.2M | +55.1% | SEC |
| Jan 24, 2025 | 75.9M | +55.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.